Desirudin Recombinant Patent Expiration

Desirudin Recombinant was first introduced by Canyon Pharmaceuticals Inc in its drug Iprivask on Apr 4, 2003.


Desirudin Recombinant Patents

Given below is the list of patents protecting Desirudin Recombinant, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Iprivask US5733874 Stable dry powders Mar 31, 2015

(Expired)

Canyon



Desirudin Recombinant's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List